Selective depletion of ABO-responsive B cells by T-cell–engaging bispecific antibody conjugates for ABOi transplantation
Authors:
- 23 April 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (17) , 1928-1940
Abstract
Organ transplantation is a pivotal treatment for patients with organ failure. ABO-incompatible (ABOi) transplantation, developed to expand the donor pool, presents significant clinical challenges due to preexisting antibodies targeting ABO antigens on donor organs. Current therapies using broad B-cell depletion, such as rituximab, effectively reduce antibody-mediated rejection but increase infection risks. Therefore, there is a critical need for targeted methods to specifically eliminate ABO-responsive B cells. Here, we developed a novel bispecific antibody-ligand conjugate (BiALC) platform designed to selectively target ABO-responsive B cells. Using synthetic trisaccharide A antigens conjugated to T-cell–recruiting Fab fragments, our optimized hexameric construct, (A3-peg)2-αCD3, demonstrated enhanced affinity and potent cytotoxicity specifically against type A antigen–responsive B cells. Notably, BiALC maintained robust efficacy even in the presence of circulating anti-A antibodies. In murine models, (A3-peg)2-αCD3 selectively depleted A-responsive B cells without broadly affecting total immunoglobulin M–positive (IgM+) and IgG+ B-cell populations, preserving overall immune competence. Similarly, the human-compatible BiALC, (A3-peg)2-αhCD3, effectively and selectively depleted type A–responsive B cells from human peripheral blood mononuclear cells, with potency comparable with that of rituximab, while sparing total antibody-secreting cells. Overall, the BiALC strategy offers a promising antigen-specific approach to reduce rejection risks in ABOi transplantation without inducing broad immunosuppression through nonspecific pan–B-cell depletion, supporting its potential for clinical translation.Keywords
This publication has 49 references indexed in Scilit:
- Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patientsJournal Of Nephrology, 2023
- Challenge to ABO blood type barrier in living donor liver transplantationHepatobiliary & Pancreatic Diseases International, 2020
- Current progress in ABO-incompatible kidney transplantationKidney Research and Clinical Practice, 2015
- Protein conjugation with genetically encoded unnatural amino acidsCurrent Opinion in Chemical Biology, 2013
- Blinatumomab: A historical perspectivePharmacology & Therapeutics, 2012
- B-1 B Cell Development in the Fetus and AdultImmunity, 2012
- An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coliJournal of Molecular Biology, 2010
- History of Solid Organ Transplantation and Organ DonationCritical Care Clinics, 2009
- Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodationClinical and Experimental Nephrology, 2007
- Enzyme-linked immunospot assay for detecting cells secreting antibodies against human blood group A epitopesTransplantation Proceedings, 2003